Skip to main content
Equibles
FATE logo

FATE · Fate Therapeutics Inc · Metrics

Track FATE — free

Use FATE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FATE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.10 +0.03 (+1.45%)
Rebalance outlook locked
Market Cap
$248.03M
Shares
119.82M
Volume · Oct 22 865.6K Avg daily vol (3M) 1.6M

FATE metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.09
Market cap
$248.03M

Price action

20 metrics
Price change (1W)
+6.7%
Price change (30D)
-19.8%
Price change (3M)
-19.8%
Price change (6M)
+51.1%
Price change (YTD)
+111.2%
Price change (1Y)
+35.3%
Trailing year
Price change (5Y)
-96.5%
52-week high
$3.11
52-week low
$0.96
Change from 52-week high
-33.4%
Change from 52-week low
+115.6%
Annualized volatility
89.9%
Annualized volatility (3M)
64.1%
Beta
2.2
RSI (14D)
43.8
Price vs SMA 50
-12.1%
Price vs SMA 200
+7.8%
Avg volume (3M)
1.61M
Relative volume
0.8
Average dollar volume
$3.93M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
119.82M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
38.2×
reciprocal yield 2.6%
P / book
1.6
reciprocal yield 61.9%
FCF yield
-42.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-50.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-05-09

Profitability

9 metrics
Gross margin
—
Operating margin
-2,058.1%
Trailing 12 months
Net margin
-1,941.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$133.59M
Net income (TTM)
−$126.00M
Trailing 12 months
Diluted EPS (TTM)
$-1.05
FCF margin
-1,627.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.05
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.12
EBITDA per diluted share (TTM)
$-1.02
Net income per diluted share (TTM)
$-1.05
Operating cash flow per diluted share (TTM)
$-0.85
Free cash flow per diluted share (TTM)
$-0.88
Capital expenditures per diluted share (TTM)
$0.03
R&D per diluted share (TTM)
$0.84
Stock compensation per diluted share (TTM)
$0.10
Book value per share
$1.80

Growth

11 metrics
Revenue growth YoY
+9.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$6.49M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.6%
Year over year · more shares
Revenue CAGR (3Y)
-59.0%
Revenue CAGR (5Y)
-26.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-82.1%
Return on assets
-48.4%
Debt / equity
—
Current ratio
4.8
EBITDA (TTM)
−$121.60M
Free cash flow (TTM)
−$105.62M
Quick ratio
4.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$32.43M
Total assets
$260.10M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$101.91M
Capital expenditures (TTM)
$3.71M
R&D (TTM)
$100.35M
SG&A (TTM)
—
Stock compensation (TTM)
$2.40M
R&D / revenue
1,546.0%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
156
13F filer change QoQ
-2
Institutional ownership
60.0%
Conviction holders (share of 13F filers)
0.6%
Crowding (high-turnover and private-fund holders)
28.9%
Private-fund adviser ownership
27.1%
Active holders' share change QoQ
+7.5%
Holder tenure
13.7
Price vs estimated holder cost
-44.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.9%

Short interest

3 metrics
Short interest
9.0%
Latest settlement · 5.3 days to cover
Days to cover
5.3d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$203,506
Insider-sentiment score
32 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1434316 CUSIP 31189P102 13F (30d) 15 filings 15 filers Visit website Investor relations